Division of Neuroscience
Alzheimer's Disease Cooperative Study (ADCS)
The Division of Neuroscience launched the ADCS in 1991 to facilitate the testing of new drugs for the treatment of Alzheimer's disease, particularly drugs that might not otherwise be tested by industry. A consortium of academic medical centers and clinics collaborating on the development of Alzheimer’s treatments and diagnostic tools, the ADCS is coordinated by the University of California, San Diego under an NIA cooperative agreement. Made up of more than 70 research sites in the United States and Canada, the ADCS investigates promising interventions. In January 2013, the NIA renewed its support of the effort for the next 5 years.
ADCS clinical trials focus on interventions that may benefit people across the disease spectrum, from the detection of Alzheimer’s-related brain changes in people free of symptoms to the treatment of agitation in people with Alzheimer’s dementia. This includes the testing of:
- Drugs that lack patent protection
- Drugs under patent protection that are already marketed for other uses but which might prove useful for treating people with Alzheimer's disease
- Novel compounds developed by individuals, academia, and pharmaceutical and small biotech companies
In addition to testing new therapies, the ADCS develops new evaluation instruments for clinical trials and innovative approaches to Alzheimer’s disease clinical trial design and analysis. The ADCS emphasizes collaboration and data sharing among its partner sites and with other research institutions.
A major component of the Division of Neuroscience’s Alzheimer’s Disease Translational Research Program, the ADCS is seeding drug development and increasing the number of promising therapies tested in people at the earliest stages of the disease, when treatment may be most effective. To date, the ADCS has conducted 30 studies (23 drug trials and seven instrument development studies). It also provides infrastructure support to other NIA-funded clinical efforts, such as the Alzheimer’s Disease Neuroimaging Initiative (ADNI) and Dominantly Inherited Alzheimer Network (DIAN).
For more information about the ADCS, including currently recruiting clinical trials, visit www.adcs.org.
| Trials | Status |
|---|---|
| Development of improved assessment measures for primary Alzheimer's disease prevention trials. | Study completed. |
| Double-blind, placebo-controlled trial of the statin drug simvastatin to slow the progression rate in Alzheimer's disease. | Study completed. |
| High-dose supplements (vitamins B6 and B12, folic acid) to reduce homocysteine and slow the rate of cognitive decline in Alzheimer's disease. | Study completed. |
| Placebo-controlled trial of valproate therapy to attenuate the clinical progression of Alzheimer's disease. | Enrollment completed; individuals are being followed. |
| Assessment of safety, tolerability, and effect on cerebrospinal fluid markers related to oxidative damage and Alzheimer’s pathology of two antioxidant combination regimens. | Study completed. |
| Randomized, double-blind, placebo-controlled trial of the effects of docosahexanoic acid (DHA) in slowing the progression of Alzheimer's disease. | Enrollment completed; individuals are being followed. |
| Multi-center trial to evaluate home-based assessment methods for Alzheimer's disease prevention research in people age 75 or older. | Enrollment began in October 2007 and is ongoing. |
| Double-blind, placebo-controlled, randomized multi-center study evaluating the efficacy and safety of 18 months of treatment with PF-04494700 (TTP488) in participants with mild to moderate Alzheimer's disease. | Enrollment began in December 2007 and is ongoing. |
| Intravaneous Immunoglobulin (IGIV) for treatment of Alzheimer's disease. | Enrollment to begin in Fall or Winter 2008. |
Printer-friendly version
Send to friend